TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3539631

Group type: EXPERIMENTAL
Intervention: Ambroxol (90 mg orally for 14 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (for 14 days)
Number of subjects: 11
Study: 29692607

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg
Number of subjects: 0
Study: 27184046

Group type: EXPERIMENTAL
Intervention: Anbainuo (etanercept)
Number of subjects: 600
Study: 24525630

Group type: EXPERIMENTAL
Intervention: Bilateral suprazygomatic maxillary nerve block with 0.15 ml/kg of 0.2% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 60
Study: 22632908

Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg intravenous recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 3035

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3035
Study: 20710058

Group type: EXPERIMENTAL
Intervention: JTK-652 (100 mg three times daily for 4 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: JTK-652
Number of subjects: 10
Study: 17050021

Group type: EXPERIMENTAL
Intervention: Imagery rehearsal in addition to normal physical therapy (12 individual sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Physical therapy only
Number of subjects: 20
Study: 16264002

Group type: EXPERIMENTAL
Intervention: Medicaid
Number of subjects: 401

Group type: COMPARATOR
Intervention: Private Insurance
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Clinics accepting Medicaid
Number of subjects: 401

Group type: COMPARATOR
Intervention: Clinics not accepting Medicaid
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: High-poverty clinics
Number of subjects: 401

Group type: COMPARATOR
Intervention: Non-high-poverty clinics
Number of subjects: 401
Study: 11904107

Group type: EXPERIMENTAL
Intervention: Calcium (1 g/d, n = 111)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo (n = 112)
Number of subjects: 223
Study: 10447535

Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV) at 80% compensation (PAV(80))
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV) at 50% compensation (PAV(50))
Number of subjects: 13

Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 13
Study: 8706195

Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms x kg(‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms x kg(‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diazepam 0.4 x kg(‐1) (active control)
Number of subjects: 60
Study: 1455195

Group type: EXPERIMENTAL
Intervention: Intravenous administration of Cyclosporin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral administration of Cyclosporin
Number of subjects: 12
Study: 4014186

Group type: EXPERIMENTAL
Intervention: Interviewer-administered questionnaire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-administered questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical variables
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet histories
Number of subjects: 0
Study: 30829137

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU weekly for 16 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 29986492

Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Fortified corn-soy blend (CSB+) with iron and folic acid (CSB+IFA)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Fortified corn-soy blend (CSB+) with multiple-micronutrient supplement (CSB+UNIMMAP)
Number of subjects: 343
Study: 26908432

Group type: EXPERIMENTAL
Intervention: Mainly exercise
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control
Number of subjects: 243
Study: 25559753

Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate and carbohydrate (WPH+CHO)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isocaloric carbohydrate (CHO)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both WPH+CHO and CHO
Number of subjects: 24
Study: 23802706

Group type: EXPERIMENTAL
Intervention: Q8003 (morphine/oxycodone combination) 12 mg/8 mg
Number of subjects: 522

Group type: COMPARATOR
Intervention: morphine 12 mg
Number of subjects: 522

Group type: COMPARATOR
Intervention: oxycodone 8 mg
Number of subjects: 522
Study: 20226390

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (mean dose, 528 IU/d)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sunlight or vitamin D supplementation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vitamin D plus calcium therapy (from Women's Health Initiative Randomized Trial)
Number of subjects: 42
Study: 19138241

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (100 mg, single dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study: 16670444

Group type: EXPERIMENTAL
Intervention: PicoElite stent (PES group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: bare metal ArthosPico stent (BMS group)
Number of subjects: 30
Study: 12833111

Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD) for 9 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Weight maintenance for one year after VLCD
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Weight maintenance after VLCD
Number of subjects: 27
Study: 10843168

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) therapy after placebo
Number of subjects: 19
Study: 7702136

Group type: EXPERIMENTAL
Intervention: Diamorphine 3 mg in bolus with bupivacaine 10 ml of 0.25% followed by infusion of bupivacaine 0.1% at 10 ml.h‐1
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Diamorphine 3 mg in infusion with bupivacaine 10 ml of 0.25% followed by infusion of bupivacaine 0.1% at 10 ml.h‐1
Number of subjects: 54
Study: 2693684

Group type: EXPERIMENTAL
Intervention: 0.125% chlorhexidine rinse
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 9
Study: 678393

Group type: EXPERIMENTAL
Intervention: Amitriptyline 6.25 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amitriptyline 12.5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nortriptyline 25 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Protriptyline 10 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: BW247 12.5 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: BW247 25 mg
Number of subjects: 24
Study: 31475493

Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication (Mannitol Injection 125 mL every 8 hours, Oxiracetam Injection 4 g once a day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Medication (Mannitol Injection 125 mL every 8 hours, Oxiracetam Injection 4 g once a day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication
Number of subjects: 70

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 70
Study: 28682897

Group type: COMPARATOR
Intervention: Difficult laryngoscopy (DL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Easy laryngoscopy (EL)
Number of subjects: 24
Study: 26152604

Group type: EXPERIMENTAL
Intervention: Low dose dabigatran (110mg bid)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Uninterrupted acenocoumarol
Number of subjects: 149
Study: 23062064

Group type: COMPARATOR
Intervention: Hand instrumentation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: WaveOne
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Reciproc
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intact control group (negative control)
Number of subjects: 40
Study: 21641951

Group type: EXPERIMENTAL
Intervention: mOPV1 A
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: mOPV1 B
Number of subjects: 1114

Group type: COMPARATOR
Intervention: tOPV X
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: mOPV1 C
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: mOPV1 D
Number of subjects: 1114

Group type: COMPARATOR
Intervention: tOPV Y
Number of subjects: 1114
Study: 18580126

Group type: EXPERIMENTAL
Intervention: Physical methods of antipyresis (e.g., cooling blankets)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External cooling methods
Number of subjects: 0
Study: 16931415

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) program including pain policy and educational program for healthcare professionals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 12680909

Group type: EXPERIMENTAL
Intervention: Motilin infusion (8 pmol (kg min)(-1) for 5 min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Motilin infusion following an antral phase III
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Motilin infusion
Number of subjects: 8
Study: 10878624

Group type: EXPERIMENTAL
Intervention: Inflow stent
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: MULTI‐LINK stent
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: NIR stent
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Palmaz‐Schatz stent
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: PURA‐A stent
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 1147
Study: 9436666

Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8421029

Group type: EXPERIMENTAL
Intervention: Intravenous dose of cephamandole at the time of tourniquet deflation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Serum concentration of cephamandole
Number of subjects: 32
Study: 3534590

Group type: EXPERIMENTAL
Intervention: Surgery plus 12 cycles of cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12 cycles of CMF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full-dose sequential non-cross-resistant combinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant CMF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proliferative activity (labeling index) of the primary tumor
Number of subjects: 0
Study: 29877872

Group type: EXPERIMENTAL
Intervention: Decompression alone
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Decompression plus fusion
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Decompression plus stabilization
Number of subjects: 85
Study: 26845175

Group type: EXPERIMENTAL
Intervention: Trabectedin (1.2 mg/m2 administered over 24 h on day 1 of a 21-d treatment cycle)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Trabectedin
Number of subjects: 30
Study: 24020826

Group type: EXPERIMENTAL
Intervention: Preservative-free timolol gel
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Preserved timolol eye drops
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy age-matched controls
Number of subjects: 40
Study: 23198943

Group type: EXPERIMENTAL
Intervention: Gum-chewing group (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (n=50)
Number of subjects: 100
Study: 20836304

Group type: EXPERIMENTAL
Intervention: Conjunctival Autograft Technique (CAG)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Minimally Invasive Pterygium Surgery (MIPS)
Number of subjects: 122
Study: 18215610

Group type: EXPERIMENTAL
Intervention: Bleeding events (no bleeding, mild bleeding, moderate bleeding, severe bleeding)
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: Moderate or severe bleeding events
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: Transfusion events
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 1235
Study: 15825917

Group type: EXPERIMENTAL
Intervention: Frontal lobe dementia patients
Number of subjects: 80

Group type: COMPARATOR
Intervention: Subcortical vascular dementia patients
Number of subjects: 80
Study: 12860778

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride, mean dosage of 95 mg/d
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride
Number of subjects: 44
Study: 10668525

Group type: EXPERIMENTAL
Intervention: Leflunomide (20 mg/day after a loading dose of 100 mg/day for 3 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methotrexate (7.5‐15 mg/week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (in US301)
Number of subjects: 0
Study: 8561065

Group type: EXPERIMENTAL
Intervention: Step 2 high-fish diet (n = 11)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Step 2 low-fish diet (n = 11)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both Step 2 diets
Number of subjects: 22
Study: 1991872

Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 44
Study: 6426992

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate 100 mg orally
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30326747

Group type: EXPERIMENTAL
Intervention: Morning Walk® group (n=28)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 58
Study: 30298808

Group type: EXPERIMENTAL
Intervention: Knowledge, attitudes, and practices (KAP) questionnaire
Number of subjects: 505
Study: 25955771

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 40
Study: 25026953

Group type: EXPERIMENTAL
Intervention: Gradient technique
Number of subjects: 223

Group type: COMPARATOR
Intervention: Swim up technique
Number of subjects: 223
Study: 22677537

Group type: EXPERIMENTAL
Intervention: 1.0 M sucrose (sweet) alone and mixed with barium
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1.0 M sodium chloride (salty) alone and mixed with barium
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.032 M caffeine (bitter) alone and mixed with barium
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Barium combined with taste
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Age (older women)
Number of subjects: 80
Study: 19388819

Group type: EXPERIMENTAL
Intervention: 200 mg dapivirine from intravaginal ring (IVR)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 25 mg dapivirine from intravaginal ring (IVR)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 200 mg dapivirine from IVR
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 25 mg dapivirine from IVR
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 200 mg and 25 mg dapivirine from IVR
Number of subjects: 25
Study: 17465499

Group type: EXPERIMENTAL
Intervention: CCL2/CCR2 mutations
Number of subjects: 284

Group type: COMPARATOR
Intervention: Non-infected matched controls
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Sustained response (SR)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Non-sustained response (NSR)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Parameters influencing fibrosis and treatment response
Number of subjects: 284
Study: 15633894

Group type: EXPERIMENTAL
Intervention: Cetirizine hydrochloride (10 mg by mouth daily for 1 week)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 11444086

Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg daily) + Vitamin C (500 mg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Vitamin C only
Number of subjects: 68
Study: 9473536

Group type: EXPERIMENTAL
Intervention: MTBE vapor exposure at 5 ppm
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MTBE vapor exposure at 25 ppm
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MTBE vapor exposure at 50 ppm
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MTBE vapor exposure (all levels)
Number of subjects: 10
Study: 7999527

Group type: EXPERIMENTAL
Intervention: MgSO4 (20 mg/kg over 10 min, followed by 10 mg/kg/h)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: MgSO4 and Saline infusion
Number of subjects: 6
Study: 3141642

Group type: EXPERIMENTAL
Intervention: Fybogel (Ispaghula husk), one sachet twice daily
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 29153919

Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 100
Study: 28777771

Group type: EXPERIMENTAL
Intervention: Family-based cognitive-behavioral therapy delivered through the Internet
Number of subjects: 138
Study: 25197005

Group type: EXPERIMENTAL
Intervention: Albuterol and ipratropium (combined therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual bronchodilator therapy (albuterol and ipratropium)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (pre-dose values)
Number of subjects: 0
Study: 24557960

Group type: EXPERIMENTAL
Intervention: Sequential therapy with amoxicillin and lansoprazole for the first 5 days and clarithromycin, ornidazole and lansoprazole for another 5 days.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard triple therapy with amoxicillin, clarithromycin, and lansoprazole for 14 days.
Number of subjects: 61
Study: 21051731

Group type: EXPERIMENTAL
Intervention: ILM peeling
Number of subjects: 141

Group type: COMPARATOR
Intervention: No peeling
Number of subjects: 141
Study: 20031690

Group type: EXPERIMENTAL
Intervention: Crush technique
Number of subjects: 424

Group type: COMPARATOR
Intervention: Culotte technique
Number of subjects: 424
Study: 16465666

Group type: EXPERIMENTAL
Intervention: Individualized home based aerobic exercise program
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Individualized home based stretching exercise program
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 39
Study: 12622343

Group type: EXPERIMENTAL
Intervention: High magnitude reinforcement condition
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low magnitude reinforcement condition
Number of subjects: 6
Study: 11207001

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 45
Study: 9046727

Group type: EXPERIMENTAL
Intervention: Adhesive precoated (APC) brackets
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control brackets
Number of subjects: 75
Study: 8396534

Group type: EXPERIMENTAL
Intervention: 750 mg of MK-0679
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3750367

Group type: EXPERIMENTAL
Intervention: Ready-to-use solution
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lyophilized form
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 12
Study: 29377592

Group type: EXPERIMENTAL
Intervention: Dairy protein supplementation (20 g d-1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Carbohydrate placebo
Number of subjects: 25
Study: 27317931

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg/day
Number of subjects: 17515

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17515
Study: 25465497

Group type: EXPERIMENTAL
Intervention: FDR-targeted decision aid (general PCa decision aid booklet plus a decision aid DVD targeted specifically for FDRs)
Number of subjects: 78

Group type: COMPARATOR
Intervention: General decision aid
Number of subjects: 78
Study: 22531237

Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP-T vaccine (group 1)
Number of subjects: 2133

Group type: COMPARATOR
Intervention: Licensed DTwP-Hep B//Hib and oral poliovirus vaccines (group 2)
Number of subjects: 2133
Study: 20447541

Group type: EXPERIMENTAL
Intervention: Elevated H‐FABP levels (> or =6 ng/ml)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Low H‐FABP levels (<6 ng/ml)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: H‐FABP levels (median 11.2 ng/ml)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: H‐FABP combined with tachycardia
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: H‐FABP levels
Number of subjects: 126
Study: 18348469

Group type: EXPERIMENTAL
Intervention: High-fat vegetarian diet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-fat non-vegetarian diet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Non-vegetarian diets
Number of subjects: 24

Group type: COMPARATOR
Intervention: High-fat non-vegetarian diet
Number of subjects: 24
Study: 15833571

Group type: EXPERIMENTAL
Intervention: Stage of Change (SOC) or ladder scales of intentions to quit, assessed at 0, 7, 14, and 30 days
Number of subjects: 115

Group type: COMPARATOR
Intervention: Two-assessment group (0 and 30 days, no intervention)
Number of subjects: 115
Study: 11997276

Group type: COMPARATOR
Intervention: TIMI grade 2/3 flow
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reduced CTFCs (faster flow)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open microvasculature (TMPG 2/3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rescue percutaneous coronary intervention (PCI) of closed arteries (TFG 0/1) at 90 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjunctive PCI of open (TFG 2/3) arteries
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patency (TFG 2/3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CTFC
Number of subjects: 0

Group type: COMPARATOR
Intervention: TMPG 2/3
Number of subjects: 0
Study: 9521968

Group type: EXPERIMENTAL
Intervention: ECMO
Number of subjects: 185

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 185
Study: 8536154

Group type: EXPERIMENTAL
Intervention: Health promotion intervention (including standard health education materials and intensive individual interventions)
Number of subjects: 4316

Group type: EXPERIMENTAL
Intervention: Health promotion intervention
Number of subjects: 4316